Astellas extends OSI tender with an eye to short-form merger
This article was originally published in Scrip
Executive Summary
Astellas has completed its initial tender bid for OSI Pharmaceuticals, but has launched a subsequent offer period in which it is hoping to raise its holding in the US firm to more than 90%.